Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer

doi:10.5306/wjco.v12.i12.1182

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3867)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

272

WORD

HTML

2159

Figures (1-2)

396

Tables (1-3)

231

Sum=3147

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

295

Download

425

Sum=720

Dec 24, 2021 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Dec 24, 2021; 12(12): 1182-1192
Published online Dec 24, 2021. doi: 10.5306/wjco.v12.i12.1182

Full Size Figure Download Figure

Figure 1 A schematic diagram showing programed death-1/ programed death ligand-1 interaction with immune cells in cancer. PD-1: Programed death-1; PD-LI: Programed death ligand-1.

Citation: Sereno M, Higuera O, Cruz Castellanos P, Falagan S, Mielgo-Rubio X, Trujillo-Reyes JC, Couñago F. Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer. World J Clin Oncol 2021; 12(12): 1182-1192
URL: https://www.wjgnet.com/2218-4333/full/v12/i12/1182.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i12.1182